

3 August 2016 EMA/529158/2016 Information Management Division

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use August 2016

This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation. It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP). For generic and biosimilar medicines, it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area.

This list only includes information for medicines whose applications have been validated at the time the report was compiled. The information in this report was compiled on **2 August 2016**.

Information on designated orphan medicines that are being assessed for marketing authorisation is also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

Information in **bold** corresponds to new entries in the monthly list.

Entries are removed from this list once the medicine has received a positive or negative opinion from the CHMP or when the applicant has withdrawn the application. The Agency publishes information on these opinions and withdrawn applications on its website.

Information on CHMP opinions is also published in the monthly CHMP highlights.



An agency of the European Union

 ${\ensuremath{\mathbb C}}$ European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged.

Non-orphan medicinal products

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ¹
Abaloparatide	Calcium homeostasis
Alectinib (hydrochloride)	Antineoplastic medicines
Anamorelin (hydrochloride)	Other therapeutic medicines
Atezolizumab	Antineoplastic medicines
Baricitinib	Immunosuppressants
Bezlotoxumab	Antidiarrheals, intestinal antiinflammatory/antiinfective medicines
Brodalumab	Immunosuppressants
Cariprazine (hydrochloride)	Psycholeptics
Cladribine	Antineoplastic medicines
Dasabuvir (sodium) / ombitasvir / paritaprevir / ritonavir	Antivirals for systemic use
Dengue tetravalent vaccine (live, attenuated)	Vaccines
Dimethyl fumarate	Antipsoriatics
Empagliflozin / linagliptin	Medicines used in diabetes
Etelcalcetide (hydrochloride)	Calcium homeostasis
Etirinotecan pegol	Antineoplastic medicines
Fluciclovine (18F)	Diagnostic radiopharmaceuticals
Follitropin delta	Sex hormones and modulators of the genital system
Human IgG1 monoclonal antibody specific for human interleukin-1 alpha	Antineoplastic medicines
Iloperidone	Psycholeptics
Insulin aspart	Medicines used in diabetes
Insulin glargine / lixisenatide	Medicines used in diabetes
Lonoctocog alfa	Antihemorrhagics
Meningococcal group B vaccine (recombinant, component, adsorbed)	Vaccines
Ocrelizumab	Immunosuppressants
Padeliporfin (di-potassium)	Antineoplastic medicines
Palbociclib	Antineoplastic medicines

 $^{^{\}rm 1}$ Based on the ATC the rapeutic sub-group.

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ¹
Patiromer sorbitex calcium	Other therapeutic medicines
Prasterone	Sex hormones and modulators of the genital system
Rolapitant	Antiemetics and antinauseants
Rurioctocog alfa pegol	Antihemorrhagics
Sarilumab	Immunosuppressants
Sodium zirconium cyclosilicate	Other therapeutic medicines
Spheroids of human autologous matrix- associated chondrocytes	Other medicines for disorders of the musculo-skeletal system
Tenofovir alafenamide (fumarate)	Antivirals for systemic use
Tofacitinib (citrate)	Immunosuppressants

Non-orphan generic and biosimilar medicinal products

International non-proprietary name / Common Name	Therapeutic area ²	Total number of applications
Adalimumab	Immunosuppressants	3
Carglumic acid	Other alimentary tract and metabolism products	1
Carmustine	Antineoplastic medicines	1
Daptomycin	Antibacterials for systemic use	1
Darunavir	Antivirals for systemic use	1
Efavirenz / emtricitabine / tenofovir disoproxil	Antivirals for systemic use	1
Emtricitabine / tenofovir disoproxil	Antivirals for systemic use	3
Ertapenem	Antibacterials for systemic use	1
Etanercept	Immunosuppressants	1
Febuxostat	Antigout medicines	1
Insulin glargine	Medicines used in diabetes	1
Ivabradine	Cardiac therapy	3
Methotrexate	Antineoplastic medicines	1
Miglustat	Other alimentary tract and metabolism products	1

 $^{\rm 2}$ Based on the ATC the rapeutic sub-group.

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use EMA/529158/2016

International non-proprietary name / Common Name	Therapeutic area ²	Total number of applications
Nitisinone	Other alimentary tract and metabolism products	1
Pegfilgrastim	Immunostimulants	4
Pemetrexed	Antineoplastic medicines	2
Pregabalin	Antiepileptics	1
Rituximab	Antineoplastic medicines	2
Sildenafil	Urologicals	1
Tadalafil	Urologicals	1
Tenofovir disoproxil	Antivirals for systemic use	1
Teriparatide	Calcium homeostasis	2
Tigecycline	Antibacterials for systemic use	1

Orphan medicinal products

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ³
Aceneuramic acid	Other medicines for disorders of the musculo-skeletal system
Alpha-1-antitrypsin	Antihemorrhagics
Amikacin	Antibacterials for systemic use
Cediranib (maleate)	Antineoplastic medicines
Chenodeoxycholic acid	Bile and liver therapy
Chlormethine	Antineoplastic medicines
Dinutuximab beta	Antineoplastic medicines
Edotreotide	Diagnostic radiopharmaceuticals
Eryaspase	Antineoplastic medicines
Expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue	Immunosuppressants
Inotuzumab ozogamicin	Antineoplastic medicines
Lutetium (177Lu) dotatate	Therapeutic radiopharmaceuticals

 $^{^{\}rm 3}$ Based on the ATC the rapeutic sub-group.

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ³
Masitinib (mesylate)	Antineoplastic medicines
Mercaptamine (hydrochloride)	Ophthalmologicals
Nonacog beta pegol	Antihemorrhagics
Obeticholic acid	Bile and liver therapy
Olaratumab	Antineoplastic medicines
Paclitaxel	Antineoplastic medicines
Pacritinib (citrate)	Antineoplastic medicines
Parathyroid hormone	Calcium homeostasis
Pentosan polysulfate sodium	Urologicals
Telotristat (etiprate)	Other alimentary tract and metabolism products
Tivozanib (hydrochloride monohydrate)	Antineoplastic medicines
Trientine (tetrahydrochloride)	Other alimentary tract and metabolism products
Venetoclax	Antineoplastic medicines
Vosaroxin	Antineoplastic medicines